Evidence map›Paper›PMID 41249585›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Optimization of the radiosynthesis of the PSMA-targeting drugs [

David Alexoff, Karl Ploessl, Ruiyue Zhao, Linlin Li, Dohyun Kim, Lin Zhu, Hank Kung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

David AlexoffFive Eleven Pharma, Inc., Philadelphia, PA, 19104, USA. david.alexoff@fiveelevenpharma.com.ORCID http://orcid.org/0000-0002-0612-1239
Karl PloesslFive Eleven Pharma, Inc., Philadelphia, PA, 19104, USA.
Ruiyue ZhaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Linlin LiDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Dongcheng District, Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing St., Beijing, 100730, China.
Dohyun KimIsotope Research and Production Department, Brookhaven National Laboratory, Upton, NY, 11973, USA.
Lin ZhuCollege of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
Hank KungFive Eleven Pharma, Inc., Philadelphia, PA, 19104, USA.

Funding

Five Eleven Pharma Inc Five Eleven Pharma Inc
6 · The paper itself

Abstract

backgroundThere is a renewed interest in radioligand therapy for cancer treatment since the approval of Lu-177 vipivotide tetraxetan (PSMA-617) by regulators in Europe and the United States for metastatic castrate resistant prostate cancer (mCRPC) patients. Recent expansion of indications for vipivotide tetraxetan in mCRPC by the FDA promises to increase demand for this class of radioligand therapy. The development of new targeted radioligands for mCRPC that improve binding specificity and increase radiation dose delivered to tumors is an active research space. [

resultsRadiolabeling of [

conclusions[

Indexed as

[177Lu]Lu-P17-087[177Lu]Lu-P17-088Automated synthesisLu-177PSMARadioligand therapy

Identifiers

PMID41249585
PMCPMC12623512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.